Cancer stem cell assay-guided chemotherapy improves survival of patients with recurrent glioblastoma in a randomized trial

Cancer stem cell assay-guided chemotherapy improves survival of patients with recurrent glioblastoma in a randomized trial

Therapy-resistant cancer stem cells (CSCs) contribute to the poor clinical outcomes of patients with recurrent glioblastoma (rGBM) who fail standard of care (SOC) therapy. ChemoID is a clinically validated assay for identifying CSC-targeted cytotoxic therapies in solid tumors.In a randomized clinica...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Tulika Ranjan, Soma Sengupta, Michael Glantz, Richard M. Green, Alexander Yu, Dawit Aregawi, Rekha Chaudhary, Ricky Chen, Mario Zuccarello, Christine Lu‐Emerson, Hugh D. Moulding, Neil D. Belman, Jon Glass, Aaron Mammoser, Mark D. Anderson, Jagan Valluri, Nicholas F. Marko, Jason Schroeder, Steven J. Jubelirer, Frances Chow, Pier Paolo Claudio, Anthony Alberico, Seth T. Lirette, Krista L. Denning, Candace M. Howard
Médium: Artigo
Jazyk:angličtina
Vydáno: 2023
On-line přístup:https://doi.org/10.1016/j.xcrm.2023.101025
https://www.cell.com/article/S2666379123001350/pdf
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Internet

https://doi.org/10.1016/j.xcrm.2023.101025
https://www.cell.com/article/S2666379123001350/pdf

Podobné jednotky